Journal
BEHAVIOURAL PHARMACOLOGY
Volume 30, Issue 1, Pages 89-94Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/FBP.0000000000000413
Keywords
behavioral dysfunction; 6-hydroxydopamine; mouse; Parkinson's disease; uric acid
Funding
- JSPS KAKENHI [15K08255]
- Central Research Institute of Fukuoka University [166006]
- Grants-in-Aid for Scientific Research [15K08255] Funding Source: KAKEN
Ask authors/readers for more resources
The development of Parkinson's disease (PD) involves the degeneration of dopaminergic neurons caused by oxidative stress. Accumulating clinical evidence indicates that high blood levels of uric acid (UA), an intrinsic antioxidative substance, are associated with reduced risk of PD. However, this hypothesis has not been confirmed by in-vivo experiments. The present study investigated the effects of UA on behavioral abnormalities in the development of PD. We used unilateral 6-hydroxydopamine-lesioned mice, which were fed on a diet containing 1% UA and 2.5% potassium oxonate (an uricase inhibitor) to induce hyperuricemia. A significant elevation in UA levels was found in groups that were fed a UA diet. The 6-hydroxydopamine-lesioned mice showed impaired rotarod performance and increased apomorphine-induced contralateral rotations. These behavioral abnormalities were significantly reversed by feeding a UA diet for 1 week before and 5 weeks after surgery (subchronic hyperuricemia). These behavioral improvements occurred in parallel with recovery of tyrosine hydroxylase protein levels in the lesioned striatal side. The present study with a dietary hyperuricemia mice model confirms that UA exerts a neuroprotective effect on dopaminergic neuronal loss, improving motor dysfunction and ameliorating PD development. Copyright (c) 2018 Wolters Kluwer Health, Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available